A Form 4 filed on September 1, 2026 with the SEC discloses that Erica Kratz, Chief Regulatory and Quality Officer of Aura Biosciences, Inc. (NASDAQ:AURA), received inducement equity awards consisting of restricted stock units and stock options on September 1, 2026.

Key Highlights

  • RSU Grant: Kratz was awarded 100,885 restricted stock units at a price of $0, representing an inducement award under an RSU agreement with the issuer.
  • RSU Vesting Schedule: The RSUs vest in four substantially equal annual installments, with the first tranche scheduled to vest on September 15, 2027, subject to continued service.
  • Stock Option Grant: Kratz was also awarded 199,115 stock options with an exercise price of $7.43, expiring on September 1, 2036.
  • Option Vesting Schedule: 25% of the options vest on August 10, 2027, with the remainder vesting pro-rata in 36 monthly installments thereafter, subject to continued service.
  • Resulting Ownership: Following the transactions, Kratz directly beneficially owns 100,885 shares of common stock and 199,115 derivative securities.
  • Filing Role: Kratz is identified as an officer with the title Chief Regulatory and Quality Officer, filing individually as one reporting person.

Erica Kratz Receives Inducement Awards at Aura Biosciences

According to the Form 4 filing, Erica Kratz, serving as Chief Regulatory and Quality Officer at Aura Biosciences, Inc. (NASDAQ:AURA), received two separate equity awards on September 1, 2026. The first is an inducement award of 100,885 restricted stock units granted pursuant to an RSU award agreement with the issuer. The filing states that each RSU "represents the right to receive one share of the Issuer's Common Stock." The acquisition is recorded at a price of $0.

The RSUs are set to vest in four substantially equal annual installments, conditioned on the reporting person's continued service as of each relevant vesting date, with the filing specifying that "the first tranche scheduled to vest on September 15, 2027." In addition, Kratz received a stock option grant of 199,115 shares of common stock with an exercise price of $7.43 per share and an expiration date of September 1, 2036, also recorded at a derivative security price of $0.

The filing describes the option vesting as follows: "25% of the options vest on August 10, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date." Both awards are held directly. The Form 4 was signed by Amy Elazzouzi as Attorney-in-Fact on September 1, 2026.

What Was Disclosed

The filing discloses two inducement equity grants to Aura Biosciences' Chief Regulatory and Quality Officer: 100,885 RSUs vesting annually beginning September 15, 2027, and 199,115 stock options at $7.43 per share expiring September 1, 2036, both subject to continued service conditions.